Interestingly, in these trials of EGFR inhibitors, EGFR expression levels in the tumors were not correlated with the response; high response rates were seen in women, patients with adenocarcinoma, nonsmokers, and Japanese patients. This evidence concerns the gene EGFR and adenocarcinoma.